Thanks for your post paladin. Just to clarify regarding Boehringer Ingelheim and Lilly, if interested they likely would be acting together as they are co-owners of the SGLT2 inhibitor Jardiance. Given Christoph Boehringer's sizeable indirect holding in RVX I think it makes this possibility interesting. 

On a related topic, it would be great if RVX might summarize, if possible, if patients in BoM on an SGLT2 inhibitor experienced fewer or lessened side effects when also on Apabetalone.